Tarsus Pharmaceuticals
Quarterly Financials
| Values in thousands | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
|---|---|---|---|---|
Revenue | $173,912 | $162,054 | $151,668 | $118,697 |
Gross Profit | 161,799 | 152,658 | 140,741 | 94,104 |
EBITDA | -12,679 | -6,754 | -3,657 | -12,125 |
EBIT | -13,679 | -7,191 | -4,100 | -12,585 |
Net Income | -18,551 | -6,967 | -8,373 | -12,585 |
Net Change In Cash | 173,912 | 162,054 | 151,668 | 118,697 |
Free Cash Flow | 62,698 | -30,470 | 12,972 | 16,347 |
Cash | 204,595 | 102,192 | 183,641 | 112,724 |
Basic Shares | 43,393 | 42,956 | 42,784 | 42,607 |
Annual Financials
| Values in thousands | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
Revenue | $451,360 | $182,953 | $17,447 | $25,816 |
Gross Profit | 420,676 | 170,127 | 15,854 | 24,861 |
EBITDA | -53,608 | -106,480 | -131,670 | -59,705 |
EBIT | -55,424 | -107,705 | -132,547 | -60,031 |
Net Income | -66,418 | -115,554 | -135,893 | -62,091 |
Net Change In Cash | 451,360 | 182,953 | 17,447 | 25,816 |
Cost of Revenue | -99,672 | |||
Free Cash Flow | -22,310 | -84,594 | -122,995 | -49,536 |
Cash | 183,641 | 94,819 | 224,947 | 71,660 |
Basic Shares | 41,784 | 37,604 | 29,383 | 24,619 |
Earnings Calls
| Quarter | EPS |
|---|---|
2026-06-30 | -$0.43 |
2026-03-31 | -$0.16 |
2025-12-31 | -$0.20 |
2025-09-30 | -$0.30 |